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Abstract
In recent years, MSCs have emerged as a promising therapeutic cell type in regenera-
tive medicine. They hold great promise for treating cardiovascular diseases, such as 
myocardial infarction and limb ischemia. MSCs may be utilized in both cell- based ther-
apy and vascular graft engineering to restore vascular function, thereby providing 
therapeutic benefits to patients. The efficacy of MSCs lies in their multipotent differ-
entiation ability toward vascular smooth muscle cells, endothelial cells and other cell 
types, as well as their capacity to secrete various trophic factors, which are potent in 
promoting angiogenesis, inhibiting apoptosis and modulating immunoreaction. 
Increasing our understanding of the mechanisms of MSC involvement in vascular re-
generation will be beneficial in boosting present therapeutic approaches and develop-
ing novel ones to treat cardiovascular diseases. In this review, we aim to summarize 
current progress in characterizing the in vivo identity of MSCs, to discuss mechanisms 
involved in cell- based therapy utilizing MSCs, and to explore current and future 
 strategies for vascular regeneration.
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I N V I T E D  R E V I E W
Mesenchymal stem cells and vascular regeneration
Wenduo Gu1  | Xuechong Hong1 | Claire Potter1 | Aijuan Qu2 | Qingbo Xu1
1  | INTRODUCTION
Cardiovascular disease is one of the leading causes of death world-
wide and is in many cases a result of vascular injury. Conventional 
small molecule therapeutics to restore blood flow have proved to be 
only partially effective and more efforts are being invested in explor-
ing the potential of stem cell- based therapy and use of engineered 
vascular grafts. Compared to the use of embryonic stem cells or in-
duced pluripotent stem cells, the use of adult stem cells has the ad-
vantages of requiring less ethical consideration and the cells being 
less tumorigenic. Among adult stem cells, MSCs stand out because of 
the ease of their isolation and their relatively high growth rates and 
short culture times, when compared to endothelial or other resident 
progenitor cells.
MSCs are plastic adherent cells isolated from various tissues and 
display multiple differentiation potentials in vitro, including the ability 
to differentiate into smooth muscle cells and endothelial cells, and can 
secrete various trophic factors, enabling them to contribute to vascu-
lar regeneration. Compared to conventional therapeutics, MSC- based 
therapy may benefit from two aspects. Vascular lineage cells differen-
tiated from MSCs are able to directly take part in forming new vessels 
for blood flow restoration and trophic factors secreted by MSCs may 
enhance existing in vivo vascular regeneration capacity. While the 
paracrine effects are more commonly seen, more evidence is needed 
to establish the direct contribution of MSC- derived SMCs and ECs in 
vivo.
In addition to the direct cell- based therapies, MSCs also have po-
tential in the development of bioengineered vessels for grafting. The 
three key components of such vascular grafts are cells, a biodegrad-
able scaffold and humoral or mechanical signals.1 A layer of endothelial 
Abbreviations used: CFU-Fs, colony-forming unit fibroblasts; EC, endothelial cell; GEFs, 
guanine exchange factors; GPCR, G-protein-coupled receptors; HOP, homeodomain-only 
protein; IGF, insulin-like growth factor; ISCT, International Society for Cellular Therapy; JNKs, 
Jun amino-terminal kinases; MAPKs, mitogen-activated protein kinase; MRTFs, myocardin-
related transcription factors; MSC, mesenchymal stem cell; PDGFRs, platelet-derived growth 
factor receptors; SMC, smooth muscle cell; SRF, serum response factor; TCE, TGF β control 
element; VEGF, vascular endothelial growth factor.
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any 
medium, provided the original work is properly cited and is not used for commercial purposes.
2 of 15  |     GU et al.
cells within the scaffold has been shown to improve thromboresis-
tance and clinical outcomes of vessel graft procedures2–4, while seed-
ing of smooth muscle cells on a biodegradable graft can enhance in 
vivo arterial wall regeneration.5–7 However, the limited life span and 
extended culture time of mature endothelial and smooth muscle cells 
has restricted their generalized use in tissue engineering. MSCs, with 
multi- lineage differentiation potential, are a valuable cell source for 
vascular engineering which do not suffer from these limitations. MSCs 
derived from the bone marrow are the most thoroughly explored type 
of MSCs.8–10 Small diameter vessels have been engineered from bone 
marrow MSCs and exhibit substantial similarity to native vessels both 
at the histological and molecular levels.11
In this review, we discuss the utilization of MSCs in vascular regen-
eration through stem cell- based therapy and vascular graft engineer-
ing, explore the mechanisms of MSC contribution in vascular disease 
and repair and highlight animal and preclinical studies which examine 
the clinical feasibility of MSC application.
2  | BASIC CONCEPTS OF MSCS
2.1 | MSCs are found in various tissue types
Bone marrow MSCs were first discovered in the 1990s by the Caplan 
group, who utilized a diffusion chamber. This chamber is formed from 
two Millipore filters enclosed by a small plastic ring. Cells injected into 
the chamber remain inside the plastic as they cannot pass through the 
filters to contact the external environment. When transplanted into an 
animal, body fluids (nutrients, salts and proteins) can pass freely through 
the filters but there is no direct contact between host cells and the cells 
inside the chamber. After transplantation of the diffusion chamber into 
the peritoneal cavity of a nude mouse, the chamber is quickly surrounded 
by host vasculature, allowing it to serve as an in vivo incubator.12–14 In 
addition to the use of a diffusion chamber, Caplan and his group also 
took advantage of porous calcium phosphate ceramics loaded with 
bone marrow cells, which they implanted at heterotopic sites (eg sub-
cutaneously). They observed that bone marrow cells in these ceramics 
predominantly formed bone while bone marrow cells in plastic diffusion 
chambers formed a mixture of bone, cartilage, and fibrous tissue.14–16
By manipulating the culture conditions,17 it was found that bone 
marrow cells can be induced into either adipocytic or osteogenic lin-
eage. This was the first evidence for the in vivo and in vitro differ-
entiation potential of bone marrow MSCs. Many subsequent studies 
have been conducted using various differentiation conditions which 
confirm that these cells can differentiate into adipocytes, osteocytes, 
and chondrocytes. It is worth noting that Caplan was also the first to 
call these cells multi- potent “MSCs”.
Since the isolation of these bone marrow MSCs with trilineage 
differentiation potential, cells with similar characteristics have been 
isolated from multiple human tissue types including adipose tissue, 
synovial membrane, periodontal ligament, tendon, skin, cartilage, den-
tal pulp, eye, gut, heart, kidney, liver, lung, muscle, pancreas, spleen, 
thymus, umbilical cord, placenta, aorta, vena cava, cord blood, and pe-
ripheral blood.18–31
These cells have shown clinical benefits in a number of areas such 
as cardiovascular disease (myocardial infarction and ischemia), pulmo-
nary disease, and neurological diseases. MSCs are also widely used in 
translational research, such as orthopedic reconstruction, which has 
promising clinical potential. Some clinical trials have taken advantage 
of the benefits of the immune regulative function of MSCs and have 
shown promising and reproducible results in immune disorders such as 
multiple sclerosis, graft- versus- host disease and Crohn’s disease.32,33
2.2 | Minimal criteria for identifying MSCs
Since 2000, there has been an increase in the number of studies fo-
cused on MSCs. However, in the absence of well- established standard 
characterization method, obvious discrepancies have been reported 
between different laboratories. This has led to difficulties in accurate 
interpretation of the results. To address this problem, ISCT published 
a position statement on the minimal criteria to define multipotent 
mesenchymal stromal cells cultured from human tissues.32 In this po-
sition paper, MSCs are defined as being adherent to a plastic surface 
when cultured under standard conditions and to acquire a specific 
phenotype and display multipotential differentiation capacity in vitro. 
(The minimal criteria for human MSC classification is summarized 
in Table 1) Surface marker expression of negative indicators CD45, 
CD34, CD14 or CD11b, CD79α, and CD19 is used to exclude contam-
ination of cultures with pan- leukocytes, primitive hematopoietic pro-
genitors, monocytes/macrophages, and B cells, respectively. Positive 
surface marker expression analysis merits further exploration because 
none of the markers currently used are MSC specific. More markers 
must also be identified to allow researchers to distinguish between 
the differentiated and undifferentiated states of MSCs.
Though the ISCT position is a start, these criteria do not exclu-
sively identify MSCs.33 Sabatini identified human bronchial fibroblasts 
exhibiting a MSC phenotype and multilineage differentiation poten-
tial in 2005. Furthermore, though these markers are used to identify 
MSCs in vitro, they have no use when attempting to identify MSCs 
in situ. MSCs in culture may be very different from those in vivo, as 
expression of some markers may be an artifact of the culture process.
Other markers used in MSC characterization include positive ex-
pression of Stro- 1,34 which can enrich CFU- Fs by approximately 100 
fold in human MSCs, in combination with a glycophorin A negative 
TABLE  1 The minimal criteria for characterizing human MSCs
Basic Characteristics Description
Plastic Adherence Plastic adherent in standard 
culture conditions
Phenotype: positive (≥95%+) 
surface markers
CD73, CD90, CD105
Phenotype: negative (≤2%+) 
surface markers
CD45, CD34, CD14 or CD11b, 
CD79α or CD19, HLA- DR
In vitro differentiation capacity Osteoblasts, adipocytes, 
chondrocytes (demonstrated 
by staining of in vitro cultures)
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phenotype (to exclude erythroid progenitors). However, Stro- 1 is only 
expressed in human tissues and there is no corresponding marker in 
other species. Recent findings also indicate that Stro- 1 is expressed in 
the endothelium rather than in mesenchymal tissue in vivo, and that 
it can be induced by in vitro MSC culture conditions.35 Additionally, 
it is well documented that differences exist across tissue origins and 
between species. This serves as evidence that further work should be 
done to identify unique markers of MSCs.
2.3 | In vivo identity and function of MSCs
MSCs are a heterogeneous population and this is reflected by the 
colonies they form in vitro, which have different growth rates and 
morphologies, ranging from fibroblast like spindle- shaped cells to 
large spread cells. Furthermore, if colonies are allowed to grow for a 
long period, heterogeneity within the colonies can also be observed, 
with some of the colonies alkaline phosphate positive, some of them 
negative, and some others positive in the center and negative in the 
periphery region.36 This heterogeneity might be explained by the fact 
that tissues themselves are made up of numerous cells and therefore 
have diverse precursor types and are heterogeneous in nature and 
origin. However, once isolated and in in vitro culture, these cells seem 
to display a number of similarities concerning phenotype and multilin-
eage differentiation potential.
To minimize the discrepancy in reported properties of MSCs and 
to increase the consistency of molecular studies and preclinical trials 
between different labs, characterization of in situ/native MSCs is a 
prerequisite for their study and could allow for improved purification 
of these cells.
Approaches to searching for the in vivo environment, localization, 
and identity of MSCs attempted so far include seeking surface markers 
expressed in vitro, infusion of labeled MSCs in vivo to track their hom-
ing and distribution, and isolation and characterization of cells from 
various tissues to determine whether they have the reported proper-
ties of MSCs.
As discussed earlier, Stro- 1 is highly expressed in stromal cells 
which are clonogenic in in vitro culture.37 Theoretically, identifying 
cells expressing high levels of Stro- 1 in ex vivo sections could identify 
the location of native MSCs, providing evidence for micro- anatomical 
niches or aiding identification of the clonogenic cells.38 A previous 
study of frozen sections stained with Stro- 1, found that the vascular 
wall was the main location for these positive cells. However, a major 
obstacle is that most surface markers expressed by MSCs cultured in 
vitro do not uniquely identify these cells and are also expressed by 
other cell types. For example, CD105 is expressed by endothelial cells 
and CD44 is expressed by smooth muscle cells. A further complica-
tion is that the phenotype of MSCs changes once they are cultured 
in vitro, which suggests that even if we could characterize cells with 
some specific markers they may not necessarily have clonogenic po-
tential in vitro. As a result, characterization of MSCs in vivo based on 
their phenotypic features is like shooting a moving target, in that the 
phenotype of MSCs constantly changes in response to their in vitro 
and in vivo microenvironment.38
Another strategy is to infuse MSCs in vivo to track their engraft-
ment and homing to specific tissues. After transducing murine bone 
marrow- derived MSCs with eGFP, labeled cells were injected system-
ically into minimally injured mice and tissue- specific differentiation of 
these cells was determined by RT- PCR and immunohistochemistry.39 
Contribution of donor- derived eGFP- MSCs to a number of different 
cell types including hepatocytes, lung epithelial cells, myofibroblasts, 
and renal tubular cells was observed. Although this approach can pro-
vide functional information about MSCs in tissue regeneration, utiliz-
ing it as a proof of the native localization of MSCs is inappropriate, as 
non- specific binding of MSCs in various tissues cannot be excluded.
Systematic isolation and evaluation of MSCs from different tissues 
represents an alternative approach.29 It has been reported in a number 
of studies that MSCs with similar in vitro characterizations can be cul-
tured from various tissues such as adipose tissue, umbilical cord, ten-
don, synovial membrane, and others. In one study, isolation of MSCs 
from tissues throughout the body (brain, kidney, liver, lung, spleen, 
bone marrow, vena cava, and aorta) provided an opportunity to consis-
tently visualize the distribution of MSCs in vivo.29 The similar though 
not identical phenotypes of MSCs originating from different tissues 
suggests that they may have similar origins but respond to differing mi-
croenvironmental influences. The proposed hypothesis that MSCs are 
tissue resident stem cells has led to further investigations into their 
perivascular origin,40 which some studies had already suggested.28,38,41 
A series of recent studies suggest that human adipose tissue pericytes 
and MSCs share a similar gene expression profile.42,43 Despite of the 
accumulating evidence indicating the perivascular origins of MSCs, 
disputes have arisen, some of which lie in the use of CD146 as a 
perivascular surface marker. CD146 is more a pericyte marker than a 
perivascular marker, and a population of CD146- negative perivascular 
cells which reside in the tunica adventitia also exhibit MSC charac-
teristics. Other studies have shown the subtle functional differences 
between pericytes and MSCs, such as in angiogenic function44, en-
graftment potential,45 and differentiation abilities42.
As none of the approaches used so far provide a definite and ex-
plicit answer to the question of the in vivo identity of MSCs, more 
studies should be done to track their development origin and elucidate 
their in vivo function.
3  | MECHANISMS OF MSC UTILIZATION 
FOR VASCULAR REGENERATION
Utilization of MSC as a therapeutic agent for vascular regeneration 
includes direct administration of MSCs either systematically or lo-
cally, to trigger and take part in vascular regeneration and indirectly 
grafting engineered vascular tissue seeded with MSCs or partially dif-
ferentiated MSCs, to relieve ischemia and restore blood flow, thus 
preventing organ damage caused by hypoxia, inflammation, and 
plaque rupture.43 In both cases, the therapeutic angiogenic potential 
of MSCs relies on their differentiation toward vascular lineages such 
as smooth muscle cells and endothelial cells as well as their paracrine 
effects. (Figure 1)
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3.1 | Differentiation towards smooth muscle cells
Developmentally, depending upon their location, vascular smooth 
muscle cells originate from different embryonic stages, forming dif-
ferent vessels or different sections of one vessel with sharp bounda-
ries.46,47 In vitro protocols for SMC differentiation utilizing stem cells 
at different embryonic stages have been established,48 which include 
treatment with all- trans retinoid acid (at- RA), TGF β and PDGF- BB, 
and culture on collagen IV, either alone or in combination. However, 
all these systems utilize in vitro culture of cells which is an intrinsic 
limitation. When interpreting experimental results, it must be con-
sidered that to what extent these in vitro systems recapitulate SMC 
 differentiation in vivo remains unknown.
The adult stem cell pool includes bone marrow cells (hematopoietic 
stem cells and MSCs), which can be mobilized and released into the 
circulation, and tissue resident stem cells (vascular progenitor cells and 
stem cells from tissues all around the body). It is possible that cells from 
both of these populations may contribute to the SMC accumulation that 
is a major event in the development of atherosclerosis. For this reason, 
efforts are being invested in exploring the origin of SMCs at the neoin-
tima. In addition, it is now recognized that these SMCs may originate 
from transdifferentiation of other cell types such as endothelial cells49,50 
and fibroblasts51,52 or from phenotypic switch of SMCs in the media.
Growing evidence is accumulating that suggests adult stem/
progenitor cells differentiate into SMCs in a variety of cardiovascu-
lar disease settings, including atherosclerosis and intra vascular stent 
restenosis. A number of in vivo studies provide evidence of the origins 
of tissue resident stem cells that give rise to SMCs in the neointima.
In 2001, Han and colleagues53 confirmed that bone marrow- 
derived cells could contribute to vascular healing, by providing an 
alternative source of smooth muscle like cells when the media is se-
verely damaged, however, they were unable to elucidate whether the 
cell type within the bone marrow taking effect was hematopoietic 
stem cells or MSCs. Later, Shimizu54 confirmed the finding of Han by 
transplantation of bone marrow galactosidase expressing cells. Sata55 
et al. took the study one step further by injecting purified hematopoi-
etic stem cells into the mouse circulation and observed that injected 
cells could participate in pathogenesis of atherosclerosis. Although 
they confirmed that hematopoietic stem cells had the potential to dif-
ferentiate into SMCs in vivo and in vitro, they did not exclude the 
possibility that the MSCs within the bone marrow could be mobilized 
by vascular injury and take part in atherosclerosis.
Despite these studies, other conflicting data exist as to whether 
bone marrow is the source for neointima SMCs. Bone marrow trans-
plantation of SM- LacZ beta- gal expressing cells into mice suggested 
that bone marrow progenitor cells did not serve as a SMC source.56 
Work from the same group also identified a type of Sca- 1(+) cells 
within the adventitia of aortic root and confirmed that after in vitro 
expansion and culture when these Sca- 1(+) positive cells were seeded 
onto the adventitia side at a site of vascular injury, the cells migrated 
into the media and intima and participated in atherosclerosis lesion 
formation and vascular repair.57
An explanation for these conflicting data is that SMA staining 
is more sensitive than SM- Laz staining. Thus, the lack of a defini-
tive marker of differentiated state SMCs means that the question of 
whether bone marrow- derived stem cells can contribute to SMC dif-
ferentiation or not remains open.
As stated earlier, several processes may contribute to SMCs pres-
ence in atherosclerotic lesions, and it remains unclear to what extent 
stem cells could give rise to SMCs in pathogenesis. What is now widely 
F IGURE  1 Mechanisms of MSC 
utilization for vascular regeneration. MSCs 
contribute to vascular regeneration by 
either being administered systematically/
locally in stem cell- based therapy or being 
utilized to construct vascular grafts. In 
both cases, their angiogenic potential 
relies on the differentiation capacity to 
smooth muscle and endothelial lineages 
as well as the paracrine effects. Functional 
improvement such as ischemia alleviation 
and blood flow restoration is achieved 
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accepted is that the origin and residency of these stem cells requires 
further exploration.
3.2 | Mechanism of smooth muscle differentiation
3.2.1 | SRF—CArG- dependent regulation of SMC 
differentiation
Serum response factor is an MADS (MCM1, agamous, deficiens, serum 
response factor) box transcription factor, which binds to the highly 
conserved CArG cis- elements (CC(A/T)6GG) that are present within 
virtually all promoter or intronic sequences of SMC marker genes, in-
cluding SMA, SM22, calponin, SMMHC, and desmin. SRF binds with 
CArG elements as a dimer and with the interaction of other co- factors 
such as myocardin, the MRTFs, and some Nkx and Gata family mem-
bers. The resulting complex has the capability to regulate SMC marker 
expression. (Figure 2) SRF is a ubiquitously expressed protein, which 
also regulates cardiac and skeletal muscle gene expression, as well as 
expression of some early response and structural genes.58 Although 
expressed widely in many cell types, the relatively high level of SRF 
within SMCs (and other muscle cell types) partly explains its specific 
regulation of muscle cell- specific genes.59,60 The ability of SRF to bind 
to CArG regions of SMC genes proves to be the rate- limiting factor in 
SMC differentiation.61
Other than myocardin and the myocardin- related family, the 
homeodomain proteins (Hox, Nkx3.1, Prx- 1, and Barx2b) also en-
hance SRF binding ability, while the HERP1/HEY262 (a target of the 
Notch signaling pathway), HOP, and YY1 possesses the ability to in-
hibit it.63–65
Post- translationally, modification of SRF by phosphoryla-
tion changes the binding affinity of SRF with transcription factors. 
Arginine vasopressin increases SM- α actin promotor activity by 
JNKs and p38 MAPKs- mediated phosphorylation of SRF at Ser103.66 
Phosphorylation at Ser162 by protein kinase Cα and at Thr159 by pro-
tein kinase A decreases SM- αactin promotor activity.67,68 Interestingly, 
CArG elements control the promotor activity of SRF,59 suggesting a 
positive feedback loop in the control system.69
The SRF- CArG regulating pathway alone is not sufficient to trigger 
SMC- specific gene expression, other cis elements and trans- binding 
factors also play a very important role in the regulation of SMC differ-
entiation, including the TCE, E box elements (CANNTG motifs), and a 
cis element referred to as a G/C repressor.70–72 Mutation of TCE and 
E box elements, which are non- CArG elements, eliminated expression 
of SMC- specific genes in transgenic mice.70,73
In summary, SMC differentiation depends on the integration of 
multiple regulatory pathways, in which SRF- CArG cis elements regula-
tion plays a critical but not exclusive role.
3.2.2 | The RhoA- regulated signaling pathway
RhoA has been proven to influence SMC differentiation in a vari-
ety of studies,74,75 and RhoA kinases are important RhoA effectors. 
Various environmental cues can promote SMC differentiation through 
the RhoA pathway including thrombin76, TGFβ77,78, S1P (sphingosine 
1 phosphate)79, BMP80, and cell stretch81. These agonists activate 
transmembrane GPCRs and with subsequent facilitation by GEFs, 
which exchange GDP for GTP, RhoA is activated.82 Details about 
the GPCR types and GEFs that respond to each agonist are reviewed 
elsewhere.83
Before RhoA activation, MRTFs bind to G- actin and remain in 
the cytoplasm. After RhoA- ROCK (RhoA kinases) pathway activation, 
however, G- actin in the cytoplasm forms F- actin and dissociates with 
MRTFs, releasing MRTFs and promoting their translocation from the 
cytoplasm to the nucleus. Increased numbers of MRTFs in the nucleus 
interact with SRF and enhance SMC- specific gene expression.84 Direct 
evidence of this nuclear translocation pattern has been observed 
using enhanced GFP fusion proteins.85 (The RhoA regulated signaling 
 pathway is depicted in Figure 2)
3.2.3 | Epigenetic modulation and micro- 
RNA regulation
Genomic DNA is wrapped in a compact structure known as chromatin, 
which is composed of nucleosomes and connected by a linker chroma-
tin. Histones (2× H2A, 2× H2B, 2× H3, 2× H4) and a 146 base pair long 
genomic DNA form the basic unit of nucleosome. The linker chroma-
tin is formed by DNA of variable lengths and histone H1. The N termi-
nal tail of histones is freely exposed to the environment and is prone 
to modifications including methylation, acetylation, phosphorylation, 
ubiquitination, and ADP- ribosylation.86 Modification of histones or 
interaction of histones with other binding proteins can change pro-
tein conformational structure and the accessibility of DNA within the 
chromatin to transcription factors.
MicroRNAs are also necessary for the differentiation of SMCs, 
as demonstrated by the study of Dicer deletion experiments, which 
resulted in the failure of microRNA maturation.87,88 Dicer deletion 
in vascular SMCs caused embryonic lethality at day 16 to 17, with 
extensive internal hemorrhage generated by reduction of SMC pro-
liferation and impaired contractility, which could be partly rescued 
by overexpression of microRNA145.89,90 Through the repression of 
antagonistic factor (Klf4, Klf5, Elk1, versican, and angiotensin con-
verting enzyme) gene expression in the SMC differentiation pro-
cess, microRNA- 143/145 facilitates expression of SMC- specific 
genes.91–95 MiR- 133 is reported recently to be able to inhibit SMC 
phenotypic switch by repressing the transcription factor Sp1 and 
regulate the expression of smooth muscle genes.96 In addition, miR- 
197,98, miR- 2199, and miR- 10a100 can also regulate smooth muscle 
differentiation.
3.2.4 | Differentiation potential of MSCs towards 
endothelial cells
MSCs from different sources have been shown to be capable of dif-
ferentiation toward an endothelial lineage. Oswald and colleagues 
showed that human bone marrow- derived MSCs could differentiate 
toward angiogenic endothelial- like cells expressing KDR and vWF by 
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simply culturing the cells in the presence of 2% fetal calf serum and 
50 ng/mL VEGF for 7 d.101 Using a canine chronic ischemia model, 
bone marrow- derived MSCs were shown to differentiate into an 
endothelial phenotype to facilitate revascularization and to improve 
heart function.102
Adipose tissue represents another important source of MSCs 
with EC differentiation ability. MSCs isolated from human adipose 
tissue can give rise to a CD34 and CD13- positive population which 
can spontaneously differentiate into endothelial cells in vitro and in 
vivo.103 Miranville et al. defined a CD34- positive, CD31- negative cell 
population from adipose tissue that could differentiate toward ECs 
in the presence of VEGF and IGF.104 More studies have further con-
firmed that MSCs isolated from adipose tissue have the capacity to dif-
ferentiate into ECs.105 However, Fischer et al. reported that although 
EC growth supplement and shear stress can induce certain endothelial 
characteristics in adipose- derived MSCs, the derived cells did not ac-
quire the full endothelial profile.106 Therefore, further modifications 
and evaluation are needed for clinical use of MSC- derived ECs as en-
dothelial replacements. Care must also be taken to distinguish adipose 
tissue- derived MSCs with EC differentiation ability from mature ECs 
that already exist in adipose tissue.107
Umbilical cord- derived MSCs also demonstrate endothelial lin-
eage commitment potential. MSCs isolated from human umbilical cord 
by explants avoided endothelial contamination and could differen-
tiate into endothelial lineages in vitro on 2D or 3D gel scaffolds, as 
well as in vivo in an ischemic hindlimb mouse model to improve limb 
perfusion.108
3.2.5 | Mechanisms involved in endothelial 
differentiation from MSCs
In addition to exploring the feasibility of using MSC as a cell popula-
tion with endothelial differentiation potential, the underlying mecha-
nisms regulating MSC to endothelial differentiation have also been 
studied. Understanding these important regulatory mechanisms can 
further help us to improve differentiation efficiency. (Mechanism of 
endothelial differentiation is depicted in Figure 3)
VEGF signaling is one of the most important signaling pathways 
that regulate vascular development and endothelial differentiation. 
Almost all protocols for MSC to endothelial differentiation include 
the supplement of VEGF in culture medium, to induce endothelial 
lineage commitment. However, the exact regulatory mechanisms of 
VEGF in MSC to endothelial differentiation are still under discussion. 
Although MSCs usually do not express VEGF receptors, it is reported 
that VEGF can generate downstream effects through PDGFRs.109 
The downregulation of PDGFRs in MSCs leads to strong inhibition 
of MSC to endothelial differentiation and MSC- mediated vasculo-
genesis.110 In addition, there are also studies that suggest VEGF 
stimulation can activate VEGFR1 expression, which further induces 
endothelial differentiation.111,112 A study showed that VEGF induced 
human and rat bone marrow- derived MSC differentiation to ECs 
through the Rho/ROCK signaling- mediated nuclear translocation of 
MRTF- A.112
Mechanical stimulation also plays important roles in regulating 
the differentiation directions of MSCs. Fluid shear stress can induce 
F IGURE  2 The RhoA pathway regulates 
SMC differentiation in response to various 
environmental cues. Thrombin, TGFβ, S1P, 
and BMP bind to GPCRs signal through 
the RhoA- ROCK pathway, which results 
in polymerization of G- actin. MRTFs go 
on to dissociate with G- actin and are 
translocated to the nucleus, where they 
activate SMC gene expression by binding 
the SRF- CArG elements
MRTFsG-actin
Thrombin, TGFβ, S1P, 
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endothelial differentiation of multiple kinds of stem cells.113 Bai et al. 
emphasized that a combination of VEGF treatment and shear stress 
stimulation can effectively induce endothelial differentiation of bone 
marrow- derived MSCs.111 Another study showed a similar effect, in 
that a combination of shear stress and VEGF can enhance endothelial 
differentiation of human adipose tissue- derived MSCs.114 By using a 
tissue- engineered vascular scaffold seeded with bone marrow- derived 
MSCs, Dong et al. showed that shear stress can induce an endothelial 
phenotype in MSCs.115 3D tubular collagen scaffolds also induce the 
differentiation of MSCs toward endothelial lineage suggesting struc-
tural environment may influence differentiation.
3.2.6 | Paracrine effects of MSCs
In studies exploring the mechanism of MSC therapy in ameliorating 
myocardial infarction, the differentiation potential of MSCs toward 
cardiomyocytes was observed, in spite of their effect in promoting 
neovascularization. However, the possible capacity of adult stem cells, 
including MSCs, to differentiate toward cardiomyocytes is a contro-
versial topic and requires further investigation.116–119 A paracrine 
mechanism of action was later proposed and further evidence showed 
that trophic factors released by MSCs could contribute to the regener-
ation of the ischemic heart.120–122 It was also demonstrated that bone 
marrow- derived MSCs overexpressing Akt could improve cardiac 
function as early as 72 h after MSC administration, which could not 
be attributed to the cardiomyocyte differentiation ability of MSCs.121 
Moreover, conditioned medium from hypoxic Akt- MSCs could signifi-
cantly attenuate ischemic damage to the heart. Consistent with the 
paracrine activity hypothesis, various trophic factors including VEGF, 
bFGF, HGF, and IGF- 1 have been shown to be upregulated in hypoxic 
Akt- MSCs compared to controls.122
Trophic factors secreted by MSCs include angiogenic factors, 
anti- apoptotic factors and immunomodulation factors.123 MSCs ex-
press angiogenic factors such as VEGF and bFGF, as well as MCP- 1 
and SDF- 1 which are essential for vascular network remodeling.120 
Optimal therapeutic angiogenesis is achieved with the participa-
tion of VEGF124, bFGF125 and angiopoietin 1125 secreted by MSCs. 
B cell lymphoma 2 (Bcl- 2), a classical inhibitor of apoptosis, can be 
synthesized and secreted by MSCs and affect nearby cells126 as well 
as themselves127. Other anti- apoptotic factors secreted include sur-
vivin and Akt.126 Furthermore, MSCs can secrete human leukocyte 
antigen class I molecule G5 (HLA- G5) and display immunosuppressive 
properties.128
4  | ANIMAL STUDIES AND CLINICAL TRIALS  
USING MSCS FOR VASCULAR REGENERATION
Vascular regeneration therapies with small molecules are proven to 
be inefficient thus far. Therefore, efforts have shifted to alternative 
stem cell therapies such as treatment with embryonic stem cells, 
induced pluripotent stem cells, and adult stem cells.43 Among adult 
stem cells, MSCs have recently emerged as an important candidate 
for vascular regenerative studies.129 For vascular tissue regeneration, 
the potential of MSCs to differentiate toward vascular smooth muscle 
and endothelial lineages upon the effect of certain chemicals or me-
chanical factors and their ability to secrete certain chemical factors 
for paracrine influence are crucial. Differentiated MSCs and secreted 
F IGURE  3 Mechanisms involved 
in regulating MSC to endothelial 
differentiation. Multiple chemical 
and mechanical stimuli regulate the 
differentiation of MSCs toward endothelial 
lineages. VEGF activates PDGF receptors 
and VEGF receptors to transmit the 
downstream signals which enhance EC 
gene expression. IGF can bind to IGF 
receptors to activate several endothelial- 
related cellular signaling pathways. Shear 
stress can trigger different sensors at the 
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trophic factors combine to promote angiogenesis and arteriogenesis 
in injured tissues, thus restoring target organ function.
4.1 | MSC- based therapy for myocardial infarction
Myocardial infarction is largely due to coronary artery diseases such 
as arthrosclerosis, restenosis and plaque rupture, which results in the 
blockade of blood flow to cardiomyocytes. Current therapeutics have 
mainly focused on modulating hemodynamics, whereas more efforts 
need to be put into exploring therapeutics that will enhance cardiac 
regeneration, among which stem cell therapy emerges to be a promis-
ing choice.130 MSCs are easily accessible and can differentiate into 
multiple cell types. In 2002, MSCs were shown to differentiate into 
cardiomyocytes in vivo, representing the basis of harnessing MSCs 
for cardiac regeneration in which massive cell replenishment is neces-
sary.131 However, limited engraftment of systematically administered 
MSCs at the infarct site and a lack of definite evidence demonstrating 
the differentiation of MSCs into cardiomyocytes has raised the recog-
nition of paracrine mechanisms which contributes to improved cardiac 
function after MSC treatment.132
In the angiogenic process that is initiated after myocardial infarc-
tion, pericytes are first removed, followed by endothelial basement 
degradation. New matrix then forms and attracts endothelial cells. 
Vessel lumen is composed of endothelial cells as well as smooth mus-
cle cells or pericytes recruited by the endothelial cells.133 In contrast 
with the controversial evidence for differentiation ability of MSCs 
into cardiomyocytes, their differentiation ability to endothelial cells 
and smooth muscle cells or pericytes is better established.101,134,135 
Increased angiogenesis contributes to enhanced vascularity and 
therefore improved cardiac function.102 The importance of paracrine 
mechanisms is addressed in experiments modifying the secretome of 
transplanted MSCs in preclinical studies.136,137 Bioinformatic analysis 
revealed that MSCs may secrete factors that are involved in various 
physiological or pathological processes including neovascularization, 
inflammation, apoptosis, and cardiac remodeling.138
Factors that may influence the efficacy of MSC therapy include 
delivery method, timing of administration, and cell type.139 Systemic 
administration of MSCs to model animals via intravenous injection was 
utilized initially but resulted in poor engraftment of the cells to infarct 
areas. Subsequently, local delivery methods such as intramyocardial, 
intracoronary, and transendocardial delivery were explored.140,141 
Intracoronary delivery may hamper coronary blood flow but is also 
associated with a higher remote engraftment rate.142 Timing of stem 
cell administration is essential as inflammation after acute myocardial 
infarction can have an impact on the survival of stem cells, thus lead-
ing to a compromised effect.139 However, no consistent conclusion 
has yet been achieved regarding the best time point for injections in 
animal studies, due to the difference in the length of studies and also 
the different ways to measure experiment outcomes. Bone marrow 
MSCs were the first to be applied in preclinical and clinical studies with 
the ease of their isolation and possibility of allogeneic cell therapy. 
Adipose tissue- derived MSCs emerged later as a promising cell source 
possessing similar properties with bone marrow MSCs and requiring a 
less invasive isolation procedure. Recent studies showed that adipose 
tissue- derived MSCs exhibit greater potential as a therapeutic agent 
for myocardial regeneration.143,144 Wharton’s jelly- derived MSCs are 
younger stem cells and also displayed efficacy in treating acute myo-
cardial infarction.145 Before they can be clinically utilized as a thera-
peutic for myocardial infarction, safety of allogeneic and autologous 
MSC stem cell therapy must be closely examined.146,147 Clinical trials 
conducted with results published in recent years are summarized in 
Table 2. Significant improvement was not achieved for all output mea-
sures and further optimization of MSC formulations is in need.
Until the mechanism for MSC driven boosting of cardiac regen-
eration is better elucidated, different approaches have to be inves-
tigated to prime MSCs to achieve more satisfying outcomes. It was 
first shown that hypoxia preconditioned MSCs enhanced regener-
ation of the infarct myocardium via trophic factors,148 and with the 
aim of controlling the MSC secretome after transplantation, genetic 
manipulations were also harnessed. Overexpression of Akt in MSCs 
inhibits ventricular remodeling through increased secretion of an-
giogenic factors such as VEGF.122 Angiogenic factor encoding genes 
can also be delivered directly to MSCs through non- viral methods.149 
Overexpression of HGF1 and SDF- 1 in MSCs has been explored with 
the purpose of mobilizing bone marrow MSCs to the infarct site.150,151 
Yet more candidates for genetic manipulation need to be identified, 
which will require a more thorough understanding of the underlying 
mechanisms through which MSCs fulfill their function.
The trend for combining biomaterials with MSCs represents a 
promising new field for study. MSCs could be incorporated in bioma-
terials and controlled by them in terms of cell fate, secretion of trophic 
factors, and engraftment rate, thus improving their efficacy in cardiac 
repair.152 Nanomaterials could serve as a non- viral method to deliver 
therapeutic factors which are essential for angiogenesis and stem cell 
recruitment.153,154 Decellularized myocardium or injectable biopoly-
mers may also serve as cell delivery platforms, which contribute to cell 
retention and facilitate heart repair.155–157
Current progress is being made in elucidating intercellular com-
munication pathways through use of microparticles containing various 
factors including protein, mRNA and miRNAs. The therapeutic poten-
tial of microparticles derived for MSCs is starting to be recognized 
as they play a vital role in intercellular communication by signaling 
through receptors on target cells or the transfer of their contents.158 
MSC- derived exosomes, a type of MSC- derived microparticles, have 
been shown to exert anti- inflammatory, anti- apoptotic, and angio-
genic effects.159–161 Eventually, if mechanisms of MSC involvement 
in improved cardiovascular outcomes are better understood, present 
stem cell- based therapies may be replaced by cell- free therapy requir-
ing only MSC- derived microparticles.
Although stem cell- based therapies in treating myocardial infarction 
are rapidly developing in recent years, challenges remain in both the pre-
clinical areas such as the standardization of cell processing procedures 
and in clinical areas including selecting the best timing for cell transplant 
and the most suitable patients. Assessment of clinical potential is based 
on the robustness of efficacy in all tested animal models including at least 
one large animal model, and efficacy with the presence of co- morbidities 
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and/or concomitant medication as recommended in the position paper 
by the European Society of Cardiology Working Group Cellular Biology 
of the Heart.162 Moreover, multicenter, randomized controlled and dou-
ble blinded studies should be undertaken to ultimately present MSC- 
based stem cell therapy as a potential routine clinical choice.
4.2 | MSC- based therapy for peripheral 
artery diseases
Peripheral artery diseases often result from occlusive artery diseases, 
typically atherosclerosis. They share risk factors with coronary artery dis-
eases including hyperlipidemia, diabetes mellitus, and hypertension.163 
Chronic ischemia of peripheral tissues leads to serious conditions, in-
cluding critical limb ischemia and amputation. Critical limb ischemia fea-
tures objective arterial occlusion and manifests as pain even at rest or 
potential tissue death. Quality of life assessment in patients with critical 
limb ischemia showed comparable patterns with end- stage cancer pa-
tients.164 The circulatory system can accommodate some changes such 
as in oxygen and nutrient needs due to the hemodynamic flexibility and 
some degree of cellular plasticity.165 However, the blood flow require-
ment of end organs exceeds any self- modulating ability in ischemia.
Therapeutic attempts in restoring vascular function have mainly 
focused on revascularization, either with the induction of angiogenesis 
by growth factors and cytokines or with surgery. VEGF and FGF both 
induce endothelial cell proliferation and migration, thus forming new 
vessel branches from existing ones.166,167 In response to shear stress 
change in the arterial stenosis, arterioles undergo a remodeling process, 
as they do not have the capacity to create new arterial branches, fea-
turing the degradation of extracellular matrix and formation of new 
three- layered arteries.168 Although the utilization of proteins that 
target post- natal angiogenesis and arteriogenesis showed promising 
results, the intrinsic limit of their short half- life has hindered their long- 
term clinical benefit. Viral delivery of genes/plasmids in vivo aims to 
achieve long- term expression of the target protein, but these effects 
come at the expense of introducing viral infection. Another feasible 
therapeutic choice would be vascular surgery, however, patients’ co- 
morbidities or vascular state might hamper this possibility.
Bone marrow is the major reservoir of both hematopoietic stem 
cells and cells with angiogenic properties, given their similar origins. 
Mononuclear cells from the bone marrow can be isolated by density 
gradient centrifugation and demonstrate angiogenic potential in isch-
emic patients.169,170 Compared to bone marrow mononuclear cells, 
MSCs possess a stronger capacity to differentiate toward smooth 
muscle cells and can be passaged ex vivo to largely reduce the bone 
marrow volumes required in clinical therapy.171,172 In a randomized 
preclinical trial conducted by Lu et al., bone marrow MSCs were 
shown to be more effective than bone marrow mononuclear cells in 
improving limb perfusion in patients with diabetic critical limb isch-
emia and foot ulcers.172 Adipose tissue- derived MSCs also exhibited 
angiogenic potential in animal studies,104,173 by inducing endothelial 
differentiation114 and secreting SDF- 1174 which can recruit endothe-
lial progenitor cells from the bone marrow to ischemic sites.
The context of stem cell therapy is essential for maximizing 
the therapeutic efficacy. Adjuvant metabolic interventions such as 
TABLE  2 Published clinical trials utilizing MSC- based therapy to treat myocardial infarction
Clinical trials Clinical condition Intervention Cell delivery route Conclusion
NCT00768066 
(TAC- HFT)
Ischemic cardiomyopathy BMMSC injection vs 
placebo; BMC injection
Transendocardial Transendocardial stem cell injection with 
MSCs or BMCs appeared to be safe.
NCT01087996 
(POSEIDON)
Ischemic cardiomyopathy Allogeneic BMMSC vs 
autologous BMMSC
Transendocardial Allogeneic and autologous MSCs could both 




Patients with chronic 
ischemic cardiomyopa-
thy undergoing CABG
BMMSC injection vs 
CABG vs no 
intervention
Intramyocardial Intramyocardial injection of autologous MSCs 
into akinetic yet non- revascularized 




Ischemic cardiomyopathy BMMSC injection Intramyocardial Autologous MSCs can be safely administered 
to the patients’ heart with chronic myocar-
dial ischemia and may be associated with 
improvements in cardiac performance and 
LV remodeling.
NCT01291329 Acute ST- elevation 
myocardial infarction
WJMSCs vs placebo Intracoronary 
infusion
Intracoronary infusion of WJMSCs is safe and 
effective in patients with AMI




Adventitial delivery of MultiStem appears safe 







dose- ranging allogeneic 
BMMSC
Intravenous Intravenous allogeneic hMSCs are safe in 
patients after acute MI
BMMSC, bone marrow mesenchymal stem cell; BMC, bone marrow mononuclear cell; CABG, coronary artery bypass grafting; WJMSC, Wharton’s jelly- 
derived mesenchymal stem cells.
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anti- oxidant and L- arginine therapy could improve neo- vascularization 
in animal studies and significantly reduce amputation rate in pilot MSC 
clinical trials.175,176 Estrogen administration and exercise also exert 
positive effects in accelerating vascular repair, relying on their anti- 
apoptotic effect and increased VEGF secretion.177,178
Stem cell- based therapy has been widely explored in therapeutic 
angiogenesis and shows a great potential, however, challenges remain 
in selecting the best end point evaluations. Current physiological end 
points include ankle- branchial index and transcutaneous oxygen pres-
sure, which are both non- invasive tests, but they mainly correlate with 
macrovascular function rather than microvascular function. Present 
imaging modalities such as ultrasound, magnetic resonance imaging 
and angiography, as well as functional outcomes such as pain- free 
walking rate and amputation free rate have also been investigated. 
Microcirculation imaging with optical coherence tomography could 
be utilized to define the microvascular function, representing a new 
means to evaluate therapeutic angiogenesis.179
4.3 | MSCs in vascular graft engineering
Cardiovascular diseases are the leading causes of medical problems all 
over the world, and often surgical bypass intervention is needed for 
treatment. One way to restore blood flow is to replace the injured or 
occluded blood vessels with engineered grafts. Saphenous veins and 
intercostal arteries are typical vascular graft candidates, but some-
times they are unavailable due to the severity of patients’ conditions 
or they have been harvested in an earlier procedure. Successful appli-
cation of synthetic grafts180 or biologically based grafts181 is limited by 
thrombosis, which may result in graft failure. As an alternative, tissue- 
engineered vascular grafts hold great promise in improving patients’ 
outcomes, as they can be designed without these limitations.
Stem cells represent a potential cell source for vascular tissue en-
gineering182 including embryonic stem cells, induced pluripotent stem 
cells, hematopoietic stem cells, and endothelial progenitor cells. SMCs 
and ECs derived from induced pluripotent stem cells have been shown 
to populate decellularized mouse aortic scaffolds to generated dual- 
seeding vessels. When such engineered vessels were grafted in vivo, 
they demonstrated better patency than cell- free scaffolds.183 A recent 
study utilized embryonic stem cell- derived c- kit+ cells as a source for 
SMCs and ECs and got encouraging results, with increased patency of 
in vivo grafted vessels for the generation of bioengineered vascular 
grafts.184 However, the application of embryonic stem cells is largely 
hampered by ethical concerns and induced pluripotent stem cells re-
quire the transfection of pluripotency factors often via viral delivery. 
Endothelial progenitors and hematopoietic stem cells are additionally 
explored for their ability to differentiate toward endothelial cells and 
subsequent potential for vascular tissue engineering.185,186 However, 
the scarcity of this cell source has limited their generalized use.
To engineer vascular grafts with mesenchymal stem cells, one 
choice is to seed undifferentiated cells onto scaffolds utilizing their 
cell recruiting abilities, and the other choice is to take advantage of 
the SMC and EC differentiation ability of MSCs in vitro and seed the 
partially differentiated cells onto scaffolds. A study published in 2007 
showed that vascular grafts engineered by seeding undifferentiated 
human MSCs from the bone marrow onto nanofibrous scaffolds exhib-
ited long- term patency compared to acellular grafts.187 Furthermore, 
the vascular grafts acquired well- organized layers of ECs and SMCs 
which mimicked native vascular tissue after being transplanted in vivo. 
In 2009, Yilin Zhao et al. exploited the differentiation ability of MSCs 
to SMC and EC like cells, and by seeding them onto decellularized 
scaffolds, they managed to develop patent, anti- thrombogenic and 
mechanically stable vascular grafts after being transplanted in vivo.188 
Further efforts in optimizing tissue- engineered vascular grafts will 
allow for expansion of opportunities for clinical application.
PERSPECTIVE
As MSCs are a promising cell type for vascular regeneration, it is im-
portant to overcome the challenges such as their heterogeneity and 
difficulties in ensuring their delivery and homing to injured tissue with 
high specificity. In addition, long- term safety data must be obtained 
before generalization of the therapy. In vivo tracking of MSCs with 
non- invasive techniques such as MRI and PET may contribute to our 
better understanding of their therapeutic effect. With sustained ef-
forts to elucidate the mechanism of MSC involvement in vascular 
regeneration, MSC- based therapies hold great promise to generate a 
paradigm shift in regenerative medicine.
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